Skip to main content
  • En
  • Français

Top Navigation

  • Newsroom
  • Contact Us

Main navigation

  • About Us
  • Products
  • Technology
  • Clinical Studies
  • Investors
  • News
  • En
  • Français

2017

Bone Therapeutics Strengthens Clinical Development Leadership with Appointment of Dr. Miguel Forte as Chief Medical Officer

  • Read more about Bone Therapeutics Strengthens Clinical Development Leadership with Appointment of Dr. Miguel Forte as Chief Medical Officer

Bone Therapeutics completes recruitment of 16 patients in ALLOB Phase I/IIA delayed-union study

  • Read more about Bone Therapeutics completes recruitment of 16 patients in ALLOB Phase I/IIA delayed-union study

Bone Therapeutics to participate in upcoming key investor conferences

  • Read more about Bone Therapeutics to participate in upcoming key investor conferences

Bone Therapeutics Reports Full Year 2016 Results

  • Read more about Bone Therapeutics Reports Full Year 2016 Results

Bone Therapeutics announces the publication of its Annual Report 2016

  • Read more about Bone Therapeutics announces the publication of its Annual Report 2016

Bone Therapeutics: The preliminary documents for the Annual General Shareholder Meeting on 26 May 2017 have been made available

  • Read more about Bone Therapeutics: The preliminary documents for the Annual General Shareholder Meeting on 26 May 2017 have been made available

Bone Therapeutics Business Update for First Quarter 2017

  • Read more about Bone Therapeutics Business Update for First Quarter 2017

Bone Therapeutics strengthens Board with the appointments of Steve Swinson and Damian Marron as Non-Executive Directors

  • Read more about Bone Therapeutics strengthens Board with the appointments of Steve Swinson and Damian Marron as Non-Executive Directors

Bone Therapeutics completes patient recruitment for pivotal interim analysis of Phase III Osteonecrosis trial with PREOB

  • Read more about Bone Therapeutics completes patient recruitment for pivotal interim analysis of Phase III Osteonecrosis trial with PREOB

Bone Therapeutics receives Intent to Grant Notice from European Patent Office for allogeneic bone cell therapy platform

  • Read more about Bone Therapeutics receives Intent to Grant Notice from European Patent Office for allogeneic bone cell therapy platform

Pagination

  • Previous page ‹‹
  • Next page ››
Subscribe to 2017
Wallonie Eu Flag

BioSenic SA
Rue Granbonpré 11 – Bâtiment H (bte 24)
1435 Mont-St-Guibert – Belgium
T.: +32 493 09 73 66
info@biosenic.com
Contact

Sign upfor our press releases

Receive information about BioSenic

Sign Up

Footer menu

  • Privacy Policy
  • Trademarks Copyrights
  • Users conditions